standards before their products can be eligible for procurement by United Nations (UN) agencies and other organizations. The requirement for validation can be seen as a synthesis of multiple international guidelines and standards, including:

• US FDA Process Validation Guidance (2011): This document emphasizes the importance of process validation throughout the lifecycle of a product. A robust validation program should encompass three stages: process design, process qualification, and continued process verification.
• EMA Annex 15: This annex recognizes validation as a critical aspect of pharmaceutical manufacturing and outlines minimum requirements for cleaning, analytical methods, and process validation.
• ICH Q8–Q11: Collectively, these guidelines detail the scientific principles behind pharmaceutical development, emphasizing necessary documentation and validation parameters.
• PIC/S Guides: These provide harmonized, high-quality standards in the pharmaceutical sector, ensuring that inspection practices align with global expectations.

These documents collectively establish a robust framework ensuring that products are consistently produced and controlled according to quality standards appropriate to their intended use.

Key Definitions Related to Validation

Understanding the key terms related to validation is essential for comprehending WHO prequalification requirements. Definitions may include:

• Validation: A documented process for obtaining, providing, and ensuring evidence that a facility, process, or method operates to its intended output consistently.
• Process Validation: A procedure for demonstrating that a manufacturing process is capable of consistently producing products that meet predetermined specifications and quality attributes.
• Cleaning Validation: A documented process for qualifying the cleaning methods used to ensure that carryover levels of residues and contaminants are within acceptable limits.
• Quality by Design (QbD): A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control.

The integration of these definitions into the validation framework used by PQ sites will ensure compliance with WHO expectations.

Validation Lifecycle Concepts

The validation lifecycle as outlined in the FDA’s 2011 guidance comprises a structured approach to process validation that aligns well with WHO prequalification requirements. The lifecycle concepts can be segmented into three key phases:

1. Process Design

This initial phase focuses on the formulation of a product and the understanding of the manufacturing process. The emphasis is on identifying critical quality attributes (CQAs) and critical process parameters (CPPs). Manufacturers must demonstrate that the process is capable of consistently delivering quality products. Documents such as risk assessments and design documents must be compiled to provide evidence of design adequacy.

2. Process Qualification

In this stage, the process is tested under conditions that reflect its intended use. This includes Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ). Each qualification stage should be meticulously documented, including batch records and validated methodologies. This evidence becomes crucial during WHO inspections as part of the prequalification process.

3. Continued Process Verification

Ongoing monitoring of the process is essential to ensure that it continues to operate within defined limits through statistical process control (SPC) or other monitoring mechanisms. This emphasizes the necessity for ongoing validation activities and routine evaluations of process data and product quality outcomes to ensure compliance with established specifications.

Documentation Requirements for WHO Prequalification

Comprehensive and well-organized documentation is essential to demonstrate compliance with WHO prequalification validation expectations. Core documents include:

Validation Master Plan (VMP)

The VMP outlines the validation strategy and provides a roadmap for validation activities of critical systems and processes. It should include timelines, responsibilities, and resource allocations, ensuring comprehensive coverage of all validation efforts involved in the production process.

SOPs and Protocols

Standard Operating Procedures (SOPs) should guide the execution of validation activities at each stage of the lifecycle. Validation protocols detailing specific test conditions, acceptance criteria, and methodologies must accompany tests to ensure reproducibility and compliance.

Validation Reports

Upon completion of validation activities, formal reports documenting findings, deviations, and conclusions must be generated. These reports should provide compelling evidence regarding the performance of a system or equipment and must be clearly justified in terms of impact on quality attributes.

Inspection Preparedness for WHO Prequalification

Inspection readiness reflects a manufacturer’s ability to present validated processes and systems comfortably to regulatory auditors. Preparing for WHO inspections necessitates a sound strategy to ensure that documentation, processes, and controls are readily available and thoroughly understood. Some best practices include:

• Conducting Pre-Inspections: Internal audits should be carried out to determine compliance with validation requirements, ensuring preparation for any potential observations made by inspectors.
• Training Staff: Personnel involved in validation must be adequately trained on the requirements and expectations under the WHO validation framework. This includes understanding how their roles align with validation activities and critical document management.
• Maintaining a Quality Management System (QMS): A robust QMS enables continuous quality improvement and facilitates the documentation, review, and implementation of validation activities. Processes such as CAPA (Corrective and Preventive Action) must be active to address any findings identified during inspections.

It is essential to create a culture that values compliance and quality throughout the organization to ensure preparedness during WHO inspections.

Conclusion: Aligning WHO Requirements with Global Standards

The validation expectations set forth by WHO prequalification are an integral part of ensuring that pharmaceutical products are safe and effective. Compliance expectations that align with international guidelines—from the US FDA’s process validation to EMA’s requirements—demonstrate the global commitment to quality assurance in drug manufacturing. Pharmaceutical manufacturers must implement robust validation practices that are cohesive and translatable across regulatory environments, enhancing the accessibility of essential medicines worldwide. By adhering to these guidelines and maintaining effective documentation and inspection preparedness, manufacturers can effectively navigate the complexities of the regulatory landscape, ultimately achieving WHO prequalification and contributing to global health outcomes.